<unk>  is an experimental gene therapy aiming to convert congenitally<unk> blind individuals to trichromats by introducing a photopigment gene that they lack. Though partial<unk><unk>  is considered only a mild disability, it is a condition that affects many people, particularly males. Complete<unk><unk> , or achromatopsia, is very rare but more severe. While never demonstrated in humans, animal studies have shown that it is possible to confer<unk>  vision by injecting a gene of the missing photopigment using gene therapy. As of 2018 there is no medical entity offering this treatment, and no clinical trials available for volunteers.
Gene therapy for color blindness
Gene therapy of the human retina
Stem cell therapy for macular degeneration
Retinal gene therapy using lentiviral vectors
Ultraviolet light therapy
Gene therapy for epilepsy
Mitochondrial replacement therapy
Vision restoration therapy